Symbols / ATRA Stock $5.01 +2.24% Atara Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ATRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Anhco Nguyen Ph.D.
Exch · Country NMS · United States
Market Cap 40.97M
Enterprise Value 42.87M
Income 32.69M
Sales 120.77M
FCF (ttm) -47.68M
Book/sh -5.26
Cash/sh 1.04
Employees 14
Insider 10d —
IPO Oct 16, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.95
Forward P/E 6.19
PEG —
P/S 0.34
P/B -0.95
P/C —
EV/EBITDA 0.83
EV/Sales 0.35
Quick Ratio 0.65
Current Ratio 0.82
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 2.57
EPS next Y 0.81
EPS Growth —
Revenue Growth -95.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-16
ROA 47.81%
ROE —
ROIC —
Gross Margin 61.79%
Oper. Margin -3.40%
Profit Margin 27.07%
Shs Outstand 8.18M
Shs Float 5.33M
Insider Own 18.33%
Instit Own 45.07%
Short Float 4.60%
Short Ratio 3.32
Short Interest 317.95K
52W High 19.14
vs 52W High -73.83%
52W Low 3.92
vs 52W Low 27.81%
Beta -0.33
Impl. Vol. —
Rel Volume 0.11
Avg Volume 237.15K
Volume 26.58K
Target (mean) $9.33
Tgt Median $6.00
Tgt Low $4.00
Tgt High $18.00
# Analysts 3
Recom None
Prev Close $4.90
Price $5.01
Change 2.24%
About

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.33
Mean price target
2. Current target
$5.01
Latest analyst target
3. DCF / Fair value
$-104.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.01
Low
$4.00
High
$18.00
Mean
$9.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-21 down Freedom Broker Buy → Sell $4
2026-01-13 down Canaccord Genuity Buy → Hold $6
2025-12-19 main Canaccord Genuity Buy → Buy $25
2025-03-11 main Canaccord Genuity Buy → Buy $17
2025-01-22 reit HC Wainwright & Co. Neutral → Neutral —
2025-01-17 main Canaccord Genuity Buy → Buy $17
2024-12-20 init Rodman & Renshaw — → Buy $25
2024-11-13 main Canaccord Genuity Buy → Buy $21
2024-08-21 reit HC Wainwright & Co. — → Neutral —
2024-08-16 up Mizuho Neutral → Outperform $18
2024-08-13 main Canaccord Genuity Buy → Buy $13
2024-07-17 main Goldman Sachs Sell → Sell $11
2024-05-22 reit HC Wainwright & Co. — → Neutral —
2024-04-01 main Stifel Hold → Hold $2
2023-11-10 main Goldman Sachs Sell → Sell $1
2023-11-09 down Evercore ISI Group Outperform → In-Line —
2023-11-09 down HC Wainwright & Co. Buy → Neutral —
2023-11-09 down Mizuho Buy → Neutral $1
2023-09-26 reit HC Wainwright & Co. Buy → Buy $28
2023-08-21 main Citigroup Sell → Sell $1
News
RSS: Latest ATRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security — 259,163 $0.00 $26
2026-03-09 GRANT-HUERTA YANINA Officer — 20,300 $0.00 $0
2026-03-02 GRANT-HUERTA YANINA Officer — 2,104 $5.08 $10,691
2026-03-02 NGUYEN ANHCO T Chief Executive Officer — 2,996 $5.08 $15,237
2026-01-12 PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security — 80,554 $6.07 $489,019
2025-11-28 PANACEA VENTURE Beneficial Owner of more than 10% of a Class of Security — 48,737 $0.00 $5
2025-11-17 GRANT-HUERTA YANINA Officer — 1,804 $13.19 $23,788
2025-11-17 NGUYEN ANHCO T Chief Executive Officer — 2,915 $13.19 $38,437
2025-08-18 GRANT-HUERTA YANINA Officer — 1,809 $11.61 $21,009
2025-08-18 NGUYEN ANHCO T Chief Executive Officer — 2,958 $11.61 $34,360
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
120.77
-6.33%
128.94
+1404.02%
8.57
-86.51%
63.57
Operating Revenue
120.77
-6.33%
128.94
+1404.02%
8.57
-86.51%
63.57
Cost Of Revenue
21.21
+0.97%
21.01
+136.43%
8.89
0.00
Reconciled Cost Of Revenue
21.21
+0.97%
21.01
+136.43%
8.89
0.00
Gross Profit
99.56
-7.76%
107.93
+34582.75%
-0.31
-100.49%
63.57
Operating Expense
63.70
-66.71%
191.37
-30.59%
275.69
-19.88%
344.09
Research And Development
37.45
-75.28%
151.48
-32.61%
224.78
-17.52%
272.53
Selling General And Administration
26.25
-34.18%
39.89
-21.65%
50.91
-28.85%
71.55
General And Administrative Expense
26.25
-34.18%
39.89
-21.65%
50.91
-28.85%
71.55
Other Gand A
26.25
-34.18%
39.89
-21.65%
50.91
-28.85%
71.55
Total Expenses
84.91
-60.02%
212.38
-25.37%
284.58
-17.29%
344.09
Operating Income
35.86
+142.98%
-83.44
+69.77%
-276.01
+1.61%
-280.51
Total Operating Income As Reported
35.86
+142.98%
-83.44
+69.77%
-276.01
+1.61%
-280.51
EBITDA
38.63
+150.99%
-75.75
+71.52%
-266.00
-19.68%
-222.26
Normalized EBITDA
38.63
+150.99%
-75.75
+71.52%
-266.00
+2.39%
-272.50
Reconciled Depreciation
2.12
-58.11%
5.05
+4.60%
4.83
-14.58%
5.65
EBIT
36.51
+145.19%
-80.80
+70.17%
-270.83
-18.83%
-227.92
Total Unusual Items
—
—
0.00
-100.00%
50.24
Total Unusual Items Excluding Goodwill
—
—
0.00
-100.00%
50.24
Special Income Charges
—
—
0.00
-100.00%
50.24
Net Income
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Pretax Income
32.72
+138.31%
-85.42
+69.06%
-276.11
-20.95%
-228.29
Net Non Operating Interest Income Expense
-3.11
-24.11%
-2.50
-1876.60%
0.14
-94.75%
2.69
Interest Expense Non Operating
3.79
-17.83%
4.62
-12.68%
5.29
+1316.89%
0.37
Net Interest Income
-3.11
-24.11%
-2.50
-1876.60%
0.14
-94.75%
2.69
Interest Expense
3.79
-17.83%
4.62
-12.68%
5.29
+1316.89%
0.37
Interest Income Non Operating
0.68
-67.63%
2.11
-61.11%
5.43
+77.38%
3.06
Interest Income
0.68
-67.63%
2.11
-61.11%
5.43
+77.38%
3.06
Other Income Expense
-0.03
-106.44%
0.53
+314.63%
-0.25
-100.50%
49.54
Other Non Operating Income Expenses
-0.03
-106.44%
0.53
+314.63%
-0.25
+64.86%
-0.70
Tax Provision
0.03
+358.33%
-0.01
-180.00%
0.01
+25.00%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Net Income From Continuing Operation Net Minority Interest
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Net Income From Continuing And Discontinued Operation
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Net Income Continuous Operations
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Normalized Income
32.69
+138.28%
-85.40
+69.07%
-276.13
+0.87%
-278.54
Net Income Common Stockholders
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Diluted EPS
—
-11.41
+82.50%
-65.19
-16.41%
-56.00
Basic EPS
—
-11.41
+82.50%
-65.19
-16.41%
-56.00
Basic Average Shares
—
7.49
+76.77%
4.24
+3.83%
4.08
Diluted Average Shares
—
7.49
+76.77%
4.24
+3.83%
4.08
Diluted NI Availto Com Stockholders
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Gain On Sale Of PPE
—
—
0.00
-100.00%
50.24
Total Other Finance Cost
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
165.50
Current Assets
101.87
Cash Cash Equivalents And Short Term Investments
51.73
Cash And Cash Equivalents
25.84
Other Short Term Investments
25.88
Receivables
34.11
Accounts Receivable
34.11
Inventory
9.71
Raw Materials
2.33
Work In Process
7.37
Prepaid Assets
—
Restricted Cash
0.15
Other Current Assets
6.18
Total Non Current Assets
63.63
Net PPE
58.79
Gross PPE
74.66
Accumulated Depreciation
-15.87
Properties
0.00
Machinery Furniture Equipment
3.12
Construction In Progress
0.16
Other Properties
70.47
Leases
0.90
Other Non Current Assets
4.84
Total Liabilities Net Minority Interest
264.74
Current Liabilities
142.23
Payables And Accrued Expenses
40.70
Payables
3.68
Accounts Payable
3.68
Current Accrued Expenses
37.01
Pensionand Other Post Retirement Benefit Plans Current
11.52
Current Debt And Capital Lease Obligation
12.18
Current Capital Lease Obligation
12.18
Current Deferred Liabilities
77.83
Current Deferred Revenue
77.83
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
122.51
Long Term Debt And Capital Lease Obligation
45.69
Long Term Capital Lease Obligation
45.69
Long Term Provisions
—
Non Current Deferred Liabilities
37.56
Non Current Deferred Revenue
37.56
Other Non Current Liabilities
39.25
Stockholders Equity
-99.23
Common Stock Equity
-99.23
Capital Stock
0.00
Common Stock
0.00
Share Issued
4.26
Ordinary Shares Number
4.26
Treasury Shares Number
0.00
Additional Paid In Capital
1,870.12
Retained Earnings
-1,969.15
Gains Losses Not Affecting Retained Earnings
-0.20
Other Equity Adjustments
-0.20
Total Equity Gross Minority Interest
-99.23
Total Capitalization
-99.23
Working Capital
-40.36
Invested Capital
-99.23
Total Debt
57.87
Capital Lease Obligations
57.87
Net Tangible Assets
-99.23
Tangible Book Value
-99.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-50.94
+25.87%
-68.72
+64.39%
-192.98
+28.64%
-270.43
Cash Flow From Continuing Operating Activities
-50.94
+25.87%
-68.72
+64.39%
-192.98
+28.64%
-270.43
Net Income From Continuing Operations
32.69
+138.28%
-85.40
+69.07%
-276.13
-20.95%
-228.30
Depreciation Amortization Depletion
2.12
-58.11%
5.05
+4.60%
4.83
-14.58%
5.65
Depreciation And Amortization
2.12
-58.11%
5.05
+4.60%
4.83
-14.58%
5.65
Other Non Cash Items
4.85
-69.37%
15.83
-5.76%
16.80
+85.40%
9.06
Stock Based Compensation
9.75
-63.88%
27.00
-40.51%
45.39
-15.70%
53.84
Asset Impairment Charge
4.13
0.00
—
—
Operating Gains Losses
—
—
—
-50.24
Gain Loss On Sale Of PPE
—
—
0.00
+100.00%
-50.24
Change In Working Capital
-104.73
-238.30%
-30.96
-301.81%
15.34
+124.96%
-61.47
Change In Receivables
0.23
-99.30%
32.63
+433.72%
6.11
+115.58%
-39.23
Changes In Account Receivables
0.23
-99.30%
32.63
+433.72%
6.11
+115.58%
-39.23
Change In Inventory
10.65
+340.30%
-4.43
+45.39%
-8.12
-411.98%
-1.59
Change In Prepaid Assets
—
—
—
—
Change In Payables And Accrued Expense
-17.46
-28.17%
-13.62
-5.34%
-12.93
-150.59%
-5.16
Change In Accrued Expense
-13.22
+7.62%
-14.31
-45.98%
-9.80
-342.05%
4.05
Change In Payable
-4.24
-717.18%
0.69
+121.95%
-3.13
+66.02%
-9.21
Change In Account Payable
-4.24
-717.18%
0.69
+121.95%
-3.13
+66.02%
-9.21
Change In Other Working Capital
-94.38
-364.84%
-20.30
-166.80%
30.39
+365.04%
-11.47
Change In Other Current Assets
6.18
+612.00%
-1.21
-191.79%
1.32
-16.18%
1.57
Change In Other Current Liabilities
-9.97
+58.50%
-24.02
-1579.51%
-1.43
+74.41%
-5.59
Investing Cash Flow
18.15
+110.44%
8.62
-93.04%
123.87
-38.97%
202.96
Cash Flow From Continuing Investing Activities
18.15
+110.44%
8.62
-93.04%
123.87
-38.97%
202.96
Net PPE Purchase And Sale
0.95
+485.37%
-0.25
+79.47%
-1.20
-101.32%
90.57
Purchase Of PPE
0.00
+100.00%
-0.25
+79.89%
-1.22
+70.83%
-4.19
Sale Of PPE
0.95
0.00
-100.00%
0.03
-99.97%
94.77
Capital Expenditure
—
-0.25
+79.89%
-1.22
+70.83%
-4.19
Net Investment Purchase And Sale
17.20
+93.91%
8.87
-92.91%
125.06
+11.28%
112.38
Purchase Of Investment
-7.88
+59.90%
-19.66
+76.49%
-83.65
+53.68%
-180.59
Sale Of Investment
25.09
-12.09%
28.54
-86.33%
208.71
-28.76%
292.97
Financing Cash Flow
16.10
-72.85%
59.28
+2849.35%
2.01
-96.21%
53.08
Cash Flow From Continuing Financing Activities
16.10
-72.85%
59.28
+2849.35%
2.01
-96.21%
53.08
Net Issuance Payments Of Debt
-0.25
+71.97%
-0.89
+5.81%
-0.95
-82.82%
-0.52
Repayment Of Debt
-0.25
+71.97%
-0.89
+5.81%
-0.95
-82.82%
-0.52
Long Term Debt Payments
-0.25
+71.97%
-0.89
+5.81%
-0.95
-82.82%
-0.52
Net Long Term Debt Issuance
-0.25
+71.97%
-0.89
+5.81%
-0.95
-82.82%
-0.52
Net Common Stock Issuance
16.31
-72.79%
59.95
+2706.69%
2.14
-90.24%
21.89
Proceeds From Stock Option Exercised
0.04
-84.78%
0.23
-75.22%
0.93
-51.69%
1.92
Net Other Financing Charges
-0.00
+85.71%
-0.01
+93.46%
-0.11
-100.36%
29.79
Changes In Cash
-16.69
-1958.45%
-0.81
+98.79%
-67.10
-366.30%
-14.39
Beginning Cash Position
25.18
-3.12%
25.99
-72.08%
93.09
-13.39%
107.48
End Cash Position
8.48
-66.31%
25.18
-3.12%
25.99
-72.08%
93.09
Free Cash Flow
-50.94
+26.13%
-68.96
+64.49%
-194.20
+29.28%
-274.62
Interest Paid Supplemental Data
0.29
-58.25%
0.69
+53.24%
0.45
+33.43%
0.34
Income Tax Paid Supplemental Data
0.19
+691.67%
0.02
+1100.00%
0.00
-89.47%
0.02
Amortization Of Securities
0.26
+207.92%
-0.24
-130.30%
0.79
-22.66%
1.02
Common Stock Issuance
16.31
-72.79%
59.95
+2706.69%
2.14
-90.24%
21.89
Issuance Of Capital Stock
16.31
-72.79%
59.95
+2706.69%
2.14
-90.24%
21.89
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category